If you have been reading about receptor agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
=== Retinoblastoma === More recent studies have identified ITGA1 as a potential therapeutic target in retinoblastoma (Rb). ITGA1 promotes Rb progression by activating the FAK/STAT3 signaling pathway. Restoration of STAT3 partially reverses the effects of ITGA1 inhibition, supporting the role of this pathway in ITGA1-mediated tumor growth. Genetic knockdown or pharmacological inhibition of ITGA1 suppresses retinoblastoma cell proliferation, migration, colony formation, and growth in vivo. Inhibition of the α1β1 integrin receptor using genetic approaches or the α1β1 inhibitor obtustatin reduces tumor progression, suggesting that ITGA1-targeted therapies may represent a potential strategy for treating high-risk retinobloastoma. However, further research and testing are needed to confirm the safety and efficacy of ITGA1 inhibition before it is used as a clinical treatment.
While fluoxetine remains the only FDA-approved antidepressant for children as young as 8, modern clinical guidelines emphasize rigorous monitoring during the first 12 weeks of treatment—the period identified as having the highest risk for the onset of suicidal ideation.
Over the next three decades, 1895–1925, as food canning was approaching a billion-dollar-a-year industry, botulism was becoming a public health hazard. Karl Friedrich Meyer, a Swiss-American veterinary scientist, created a center at the Hooper Foundation in San Francisco, where he developed techniques for growing the organism and extracting the toxin, and conversely, for preventing organism growth and toxin production, and inactivating the toxin by heating. The California canning industry was thereby preserved.
"... the death penalty is primarily a criminal justice issue, and therefore is a question for the sovereign jurisdiction of each country [...] the right to life is not the only right, and [...] it is the duty of societies and governments to decide how to balance competing rights against each other." In January 2004, the Ministry of Home Affairs issued a response to Amnesty International's report, "Singapore: The death penalty - A hidden toll of executions". It defended Singapore's policy to retain the death penalty, predicating its arguments on, among others, the following grounds:
Sources: en.wikipedia.org
Heroin-assisted treatment (HAT), or diamorphine-assisted treatment, refers to a type of Medication-Assisted Treatment (MAT) where semi-synthetic heroin is prescribed to opioid addicts who do not benefit from, or cannot tolerate, treatment with one of the established drugs used in opioid replacement therapy such as methadone or buprenorphine/naloxone (brand name Suboxone). For this group of patients, heroin-assisted treatment has proven superior in improving their social and health situation. Heroin-assisted treatment is fully a part of the national health system in Switzerland, Germany, the Netherlands, Canada, and Denmark. Additional trials are being carried out in the United Kingdom, Norway, and Belgium.
no free IP would have improved anything related to this pandemic." His foundation has instead helped other countries reach licensing deals as in the case of the Oxford/AstraZeneca vaccine being produced by India's Serum Institute. Another concern, raised by Pfizer CEO Albert Bourla, is that allowing unauthorized third-party vaccine production would severely disrupt vaccine developers' efforts to ramp up vaccine production when original developers and third-party producers all end up competing for the same scarce raw materials. This is why some conclude that voluntary technology transfers are the superior option for producing more doses—since the transferor's active assistance can help the transferee bypass time-consuming clinical trials by taking advantage of existing approvals for the transferor's vaccine—and others describe patent waiver proposals as "more symbolic than practical". Derek Lowe has characterized the U.S. government's May 2021 announcement of support for patent waiver proposals as "almost as much of a PR move as anything else". By November 2021, the prospects for approval of such proposals (which by WTO tradition must be unanimous) looked increasingly remote; participants criticized the United States for not working to bridge the gap between supporters and opponents. Meanwhile, Tedros Adhanom Ghebreyesus has rejected the dichotomy between waiving patents and initiating technology transfers by including both measures as part of a list of four steps towards increasing vaccine production.
== Portrayals in television == Television is in over 90% of U.S. households and in 1995 it had a strong influence on how viewers perceive the world. In terms of mental illness portrayals, television has been a pioneer in representing these illnesses across thousands of programs in nearly a century's worth of content. The media often depicts people with mental illness as violent or unpredictable, creating misrepresentations and harmful stereotypes. Research shows that viewers who watch more television are more likely to have negative views about mental health. Although television has frequently misrepresented mental health, there has been a growing shift towards more accurate and honest portrayals.
Sources: en.wikipedia.org
Methaqualone is a sedative-hypnotic medication that was widely prescribed during the mid-20th century. It was marketed under various brand names, including Quaalude ( KWAY-lood) and Sopor, typically containing 300 mg of methaqualone per tablet. A combination drug known as Mandrax was sold primarily in Europe, containing 250 mg of methaqualone and 20 mg of diphenhydramine in a single tablet. Methaqualone belongs to the quinazolinone class of compounds. Its commercial production was discontinued in many countries during the mid-1980s due to widespread misuse, addiction, and associated public health concerns. However, methaqualone continues to be used as a recreational drug in certain places such as South Africa. In addition, methaqualone analogues with greater than 100-fold potency such as mephenaqualone have emerged as novel designer drugs in the late 2010s and early 2020s.
On March 23, Twitter announced it would remove blue checkmarks from "legacy" verified accounts on April 1, or April Fools' Day. Twitter subsequently stopped distinguishing Twitter Blue subscribers from legacy verified accounts on April 2. On April 19, the Twitter Verified account tweeted that, on April 20, legacy verified checkmarks would disappear, in apparent reference to the cannabis slang number 420; Musk had previously tweeted about the April 20 date on April 11. Despite skepticism due to the date, Twitter began removing legacy checkmarks on April 20, 2023. Among those that lost their verified status included Cristiano Ronaldo and Beyoncé. Actress Halle Berry posted a meme commemorating the loss of her blue checkmark. Several figures, such as Stephen King, noted that they had not paid for verification and—in King's case—had not added a phone number to their account. While some users, such as Eliot Higgins of Bellingcat appear to have been given verification for free, others, such as actor Ryan Reynolds—whose Twitter account has 21 million followers—do not. NBC News noted that legacy verified accounts still appeared in search results filtering for just verified users. The Washington Post noted that several deceased individuals, such as basketball player Kobe Bryant, actor Chadwick Boseman, celebrity chef Anthony Bourdain, and Linkin Park vocalist Chester Bennington had a blue checkmark. Other figures with blue checkmarks include singer Michael Jackson, rapper Mac Miller, and senator John McCain.
There are three types of myomeres observed in fish-like chordates: amphioxine (lancelet), cyclostomine (jawless fish), and gnathostomine (jawed fish). All myomeres flex the body laterally into concavity to provide force for locomotion. Since myomeres are composed of multinucleated myofibers (contractile cells), force can be generated via muscle contraction that gets transmitted by the intricate connective tissue (myosepta) network. Myomeres compose most of the lateral musculature and provide propulsive force to travel along the line of travel. In this sense, they cause flexion to either side in order to produce locomotor force (the forward swimming motion). Myomeres attach to centra of vertebrae, and neural and haemal spines. The folded shape of each myomere as V- or W-shaped extends over various axial segments, allowing fibers control over a large amount of the body. There are different variations of myomere activation depending on the type of swimming or movement. For example, high loading situations such as fast-starts and turning require almost maximal myomere activation in teleost fish. Further, if swim speeds are lower and movement is in one plane, there is less activation of myomeres. Research has discovered that fish are able to spatially restrict axial myomeres during different swimming behaviors.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.